KR102796519B1 - Skin whitening composition for oral administration comprising glutathione - Google Patents
Skin whitening composition for oral administration comprising glutathione Download PDFInfo
- Publication number
- KR102796519B1 KR102796519B1 KR1020230082776A KR20230082776A KR102796519B1 KR 102796519 B1 KR102796519 B1 KR 102796519B1 KR 1020230082776 A KR1020230082776 A KR 1020230082776A KR 20230082776 A KR20230082776 A KR 20230082776A KR 102796519 B1 KR102796519 B1 KR 102796519B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin whitening
- vitamin
- glutathione
- whitening composition
- oral administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 230000002087 whitening effect Effects 0.000 title claims abstract description 61
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 60
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 26
- 229960003180 glutathione Drugs 0.000 title claims abstract description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 37
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 27
- 239000008103 glucose Substances 0.000 claims abstract description 27
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 18
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 18
- 239000011718 vitamin C Substances 0.000 claims abstract description 18
- 229960003080 taurine Drugs 0.000 claims abstract description 14
- 235000016709 nutrition Nutrition 0.000 claims abstract description 11
- 230000035764 nutrition Effects 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 claims description 8
- 229940041514 candida albicans extract Drugs 0.000 claims description 8
- 239000012138 yeast extract Substances 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 239000004376 Sucralose Substances 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 6
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 239000007968 orange flavor Substances 0.000 claims description 6
- 235000015205 orange juice Nutrition 0.000 claims description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 6
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 2
- 244000228451 Stevia rebaudiana Species 0.000 claims 2
- 239000003707 silyl modified polymer Substances 0.000 claims 2
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 abstract description 6
- 230000001747 exhibiting effect Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 14
- 230000036541 health Effects 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000019629 palatability Nutrition 0.000 description 5
- 241000544066 Stevia Species 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001058 brown pigment Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000015897 energy drink Nutrition 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 108091005995 glycated hemoglobin Proteins 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/61—Glucose, Dextrose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
글루타치온을 포함하는 경구 투여용 피부 미백 조성물이 개시된다. 본 발명에 따른 경구 투여용 피부 미백 조성물은 수분과 영양 섭취를 위한 경구 투여용 조성물에 있어서, 인체에 필요한 영양과 다양한 생리활성에 도움이 되는 구성성분으로 포도당과 타우린을 포함하고, 피부 미백효과를 발휘하는 구성성분으로 글루타치온과 비타민 C를 포함한다.An oral skin whitening composition containing glutathione is disclosed. The oral skin whitening composition according to the present invention is an oral composition for moisture and nutrition intake, which contains glucose and taurine as components helpful for nutrition necessary for the human body and various physiological activities, and glutathione and vitamin C as components exhibiting a skin whitening effect.
Description
본 발명은, 경구 투여용 피부 미백 조성물에 관한 것으로, 더 상세하게는 원활한 수분 섭취를 위해 기호성과 함께 인체에 필요한 영양 섭취가 가능하도록 적정량의 물과 함께 섭취하는 건강보조식품 또는 건강기능식품으로 제공되거나 의약품으로 제공되는 피부 미백효과가 있는 경구 투여용 피부 미백 조성물에 관한 것이다.The present invention relates to a skin whitening composition for oral administration, and more specifically, to a skin whitening composition for oral administration having a skin whitening effect, which is provided as a health supplement or health functional food to be taken with an appropriate amount of water to enable the intake of nutrients necessary for the human body along with palatability for smooth water intake, or as a pharmaceutical product.
수분은 인간이 생명과 건강을 유지하는 필수 성분으로 성인 몸무게의 약 60%를 차지하고 있으며 혈량을 유지하고 체내에서 영양소를 공급하거나 노폐물 배설의 중요한 역할을 하고 있다.Water is an essential element for humans to maintain life and health, accounting for approximately 60% of an adult's body weight. It plays an important role in maintaining blood volume, supplying nutrients to the body, and excreting waste.
적절한 수분은 인체의 항상성 유지와 면역력 증진,변비 예방에도 필수적임. 하루 수분 필요량은 나이, 체중, 기온,활동량이나 인체 칼로리 소모량에 따라 달라지는데 한국인 영양소 섭취기준의 국민건강영양조사 자료에 따르면 국민 중 약 6 2%가 수분 섭취 기준을 충족하지 못하는 수준으로 조사되어 수분 섭취의 중요성이 더욱 대두되고 있다.Adequate water is essential for maintaining homeostasis, boosting immunity, and preventing constipation. The daily water requirement varies depending on age, weight, temperature, activity level, and body calorie consumption. According to the National Health and Nutrition Survey data of the Korean Nutrient Intake Standard, approximately 62% of the population does not meet the water intake standard, which highlights the importance of water intake.
이러한 실정를 감안하여 최근에는 원활한 수분 섭취를 위해 기호성과 함께 인체에 필요한 영양 성분들을 포함한 다양한 수분 보충제 제품들 혹은 에너지/스포츠 음료 제품들이 개발되어 건강보조식품 또는 건강기능식품으로 널리 판매되고 있다.Considering these circumstances, various water supplement products or energy/sports drinks that contain the nutrients necessary for the human body along with palatability have been developed recently to facilitate smooth water intake and are widely sold as health supplements or health functional foods.
그런데, 이들 종래의 수분 보충제 제품은 원활한 수분 섭취와 함께 피로 회복에 도움이 되는 흔히 알려진 영양 성분들을 제공하는데 그치고 있어서, 수분과 영양 섭취에 대한 니즈와 더불어 피부 개선 등의 복합적인 효과를 기대하는 최근 소비자의 니즈를 충족시키는데 한계가 있었다.However, these conventional moisture supplement products only provide commonly known nutritional ingredients that help with smooth moisture intake and fatigue recovery, so they have limitations in meeting the needs of recent consumers who expect combined effects such as skin improvement along with the need for moisture and nutrition intake.
관련 선행기술문헌으로는 등록특허공보 제10-2105111호(발명의 명칭: 생리활성성분이 강화된 에너지 음료 조성물 및 그 제조방법, 공고일자: 2020년 04월 27일) 및 등록특허공보 제10-2435548호(발명의 명칭: 액상스틱형 에너지 스포츠 음료, 공고일자: 2022년 08월 26일) 등이 있다.Related prior art documents include Patent Registration No. 10-2105111 (Title of the invention: Energy drink composition with enhanced physiologically active ingredients and its manufacturing method, Publication date: April 27, 2020) and Patent Registration No. 10-2435548 (Title of the invention: Liquid stick-type energy sports drink, Publication date: August 26, 2022).
본 발명의 목적은, 건강보조식품, 건강기능식품, 의약품 등에 있어서, 원활한 수분 섭취를 위해 기호성과 함께 인체에 필요한 영양 섭취가 가능하면서도 피부 미백효과를 발휘하는 경구 투여용 피부 미백 조성물을 제공하는 것이다.The purpose of the present invention is to provide a skin whitening composition for oral administration, which enables the intake of nutrients necessary for the human body along with palatability for smooth water intake in health supplements, health functional foods, pharmaceuticals, etc., while also exhibiting a skin whitening effect.
상기 목적은, 본 발명의 일 실시예에 따라, 수분과 영양 섭취를 위한 경구 투여용 조성물에 있어서, 포도당 및 글루타치온을 구성성분으로 포함하는 것을 특징으로 하는 글루타치온을 포함하는 경구 투여용 피부 미백 조성물에 의해 달성된다.The above object is achieved by an oral skin whitening composition comprising glutathione, characterized in that it comprises glucose and glutathione as components in an oral composition for moisture and nutrition intake, according to one embodiment of the present invention.
바람직하게, 상기 글루타치온은 L-글루타치온 효모추출물로 제공될 수 있다.Preferably, the glutathione may be provided as L-glutathione yeast extract.
바람직하게, 상기 경구 투여용 피부 미백 조성물은 비타민 C를 구성성분으로 더 포함할 수 있다.Preferably, the skin whitening composition for oral administration may further comprise vitamin C as a component.
바람직하게, 상기 글루타치온은 상기 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 2~8중량%로 포함되고, 상기 비타민 C는 상기 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 1~5중량%로 포함될 수 있다.Preferably, the glutathione may be included in an amount of 2 to 8 wt% based on the total weight of the skin whitening composition for oral administration, and the vitamin C may be included in an amount of 1 to 5 wt% based on the total weight of the skin whitening composition for oral administration.
바람직하게, 상기 경구 투여용 피부 미백 조성물은 타우린 및 정제소금을 구성성분으로 더 포함할 수 있다.Preferably, the skin whitening composition for oral administration may further comprise taurine and purified salt as components.
바람직하게, 상기 글루타치온은 상기 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 2~8중량%로 포함되고, 상기 비타민 C는 상기 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 1~5중량%로 포함되며, 상기 타우린은 상기 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 2~8중량%로 포함되고, 상기 정제소금은 상기 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 0.5~1.5중량%로 포함될 수 있다.Preferably, the glutathione may be included in an amount of 2 to 8 wt% based on the total weight of the skin whitening composition for oral administration, the vitamin C may be included in an amount of 1 to 5 wt% based on the total weight of the skin whitening composition for oral administration, the taurine may be included in an amount of 2 to 8 wt% based on the total weight of the skin whitening composition for oral administration, and the refined salt may be included in an amount of 0.5 to 1.5 wt% based on the total weight of the skin whitening composition for oral administration.
바람직하게, 상기 경구 투여용 피부 미백 조성물은 분말 제형으로 제조되어 사용자가 이를 적정량의 물에 혼합하여 섭취할 수 있다.Preferably, the skin whitening composition for oral administration is prepared in a powder form so that the user can mix it with an appropriate amount of water and ingest it.
본 발명은, 건강보조식품, 건강기능식품, 의약품 등으로 제공되는 경구 투여용 피부 미백 조성물에 있어서, 인체에 필요한 영양과 다양한 생리활성에 도움이 되는 구성성분과 피부 미백효과를 발휘하는 구성성분을 포함함으로써, 원활한 수분 섭취를 위해 기호성과 함께 인체에 필요한 영양 섭취가 가능하면서도 피부 미백효과를 발휘할 수 있다.The present invention relates to a skin whitening composition for oral administration provided as a health supplement, health functional food, medicine, etc., which comprises components that are helpful for nutrition and various physiological activities necessary for the human body and components that exhibit a skin whitening effect, thereby enabling the intake of nutrients necessary for the human body along with palatability for smooth water intake, while exhibiting a skin whitening effect.
이하, 본 발명의 바람직한 실시예들을 구체적으로 상세히 설명한다. 다만, 본 발명을 설명함에 있어서 이미 공지된 기능 혹은 구성에 대한 설명은, 본 발명의 요지를 명료하게 하기 위하여 생략하기로 한다.Hereinafter, preferred embodiments of the present invention will be described in detail. However, in explaining the present invention, descriptions of functions or configurations already known will be omitted in order to clarify the gist of the present invention.
본 발명은 건강보조식품/건강기능식품으로 제공되거나 의약품으로 제공되는 경구 투여용 피부 미백 조성물에 관한 것이다. 즉, 본 발명에 따른 경구 투여용 피부 미백 조성물은 원활한 수분 섭취를 위해 기호성과 함께 인체에 필요한 영양 섭취가 가능하게 하면서도 피부 미백효과를 발휘하는 것으로, 피부 미백용 기능성식품(건강보조식품/건강기능식품)이거나 피부 미백용 약학 조성물일 수 있다.The present invention relates to a skin whitening composition for oral administration provided as a health supplement/health functional food or as a pharmaceutical product. That is, the skin whitening composition for oral administration according to the present invention enables the intake of nutrients necessary for the human body along with palatability for smooth water intake, while exhibiting a skin whitening effect, and may be a skin whitening functional food (health supplement/health functional food) or a skin whitening pharmaceutical composition.
본 발명에 따른 경구 투여용 피부 미백 조성물은 인체에 필요한 영양과 다양한 생리활성에 도움이 되는 구성성분과 피부 미백효과를 발휘하는 구성성분을 포함하고 있다. 그리고, 본 발명에 따른 경구 투여용 피부 미백 조성물은 사용자(섭취자)가 적정량의 물에 혼합하여 섭취하도록 분말 혹은 가루 제형으로 제조되는 것이 바람직하다. 바람직하게, 본 발명에 따른 경구 투여용 피부 미백 조성물은 사용자가 섭취하기 편하게 한 포 단위로 포장되는데, 예컨대 한 포당 10g 단위로 포장되는 경우 물 250~350㎖에 혼합하여 섭취하도록 권장될 수 있다. 다만, 이와 다르게 본 발명에 따른 경구 투여용 피부 미백 조성물은 정제 제형으로 제조될 수 있다.The skin whitening composition for oral administration according to the present invention contains components that are helpful for nutrition and various physiological activities required by the human body, and components that exhibit a skin whitening effect. In addition, the skin whitening composition for oral administration according to the present invention is preferably manufactured in a powder or powder form so that a user (intake user) can mix it with an appropriate amount of water and ingest it. Preferably, the skin whitening composition for oral administration according to the present invention is packaged in a single sachet for the user's convenience. For example, in the case of packaging in a 10g unit per sachet, it may be recommended to mix it with 250 to 350ml of water and ingest it. However, differently from this, the skin whitening composition for oral administration according to the present invention may be manufactured in a tablet form.
이하, 본 발명에 따른 경구 투여용 피부 미백 조성물의 인체에 필요한 영양과 다양한 생리활성에 도움이 되는 구성성분과 피부 미백효과를 발휘하는 구성성분, 그리고 다른 기능성 구성성분의 구체적인 배합 및 그 함량에 대하여 상세히 설명한다.Hereinafter, the specific combination and content of the components that provide nutrition necessary for the human body and help with various physiological activities, the components that exert a skin whitening effect, and other functional components of the skin whitening composition for oral administration according to the present invention will be described in detail.
본 발명의 일 실시예에 따른 경구 투여용 피부 미백 조성물은 인체에 필요한 영양과 다양한 생리활성에 도움이 되는 구성성분으로 포도당과 타우린을 포함하고, 피부 미백효과를 발휘하는 구성성분으로 글루타치온과 비타민 C를 포함한다. 또한, 본 발명의 일 실시예에 따른 경구 투여용 피부 미백 조성물은 정제소금을 구성성분을 더 포함한다.An oral skin whitening composition according to one embodiment of the present invention comprises glucose and taurine as components that are helpful for nutrition and various physiological activities required by the human body, and glutathione and vitamin C as components that exhibit a skin whitening effect. In addition, an oral skin whitening composition according to one embodiment of the present invention further comprises purified salt as a component.
여기서, 포도당은 무수결정 포도당으로 제공되고 경구 투여용 피부 미백 조성물의 전체 중량(100중량%)에 대하여 42~72중량%로 포함되는 것이 바람직하며, 타우린은 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 2~8중량%로 포함되는 것이 바람직하다. 그리고, 글루타치온은 L-글루타치온 효모추출물로 제공되고 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 2~8중량%로 포함되는 것이 바람직하며, 비타민 C는 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 1~5중량%로 포함되는 것이 바람직하고, 정제소금은 경구 투여용 피부 미백 조성물의 전체 중량에 대하여 0.5~1.5중량%로 포함되는 것이 바람직하다.Here, glucose is preferably provided as anhydrous crystalline glucose and is contained in an amount of 42 to 72 wt% based on the total weight (100 wt%) of the skin whitening composition for oral administration, and taurine is preferably contained in an amount of 2 to 8 wt% based on the total weight of the skin whitening composition for oral administration. In addition, glutathione is provided as L-glutathione yeast extract and is preferably contained in an amount of 2 to 8 wt% based on the total weight of the skin whitening composition for oral administration, vitamin C is preferably contained in an amount of 1 to 5 wt% based on the total weight of the skin whitening composition for oral administration, and refined salt is preferably contained in an amount of 0.5 to 1.5 wt% based on the total weight of the skin whitening composition for oral administration.
즉, 본 발명의 일 실시예에 따른 경구 투여용 피부 미백 조성물은 그 전체 중량(100중량%)에 대하여 포도당(무수결정 포도당) 42~72중량%, 타우린 2~8중량%, 글루타치온(L-글루타치온 효모추출물) 2~8중량%, 비타민 C 1~5중량% 및 정제소금 0.5~1.5중량%를 포함하는 것이 바람직하다. 더 바람직하게, 본 발명의 일 실시예에 따른 경구 투여용 피부 미백 조성물은 그 전체 중량에 대하여 포도당(무수결정 포도당) 47~57중량%, 타우린 3~7중량%, 글루타치온(L-글루타치온 효모추출물) 3~7중량%, 비타민 C 2~4중량% 및 정제소금 0.75~1.25중량%를 포함할 수 있다. 그리고, 가장 바람직하게 본 발명의 일 실시예에 따른 경구 투여용 피부 미백 조성물은 그 전체 중량에 대하여 포도당(무수결정 포도당) 56.83중량%, 타우린 5중량%, 글루타치온(L-글루타치온 효모추출물) 5중량%, 비타민 C 3중량% 및 정제소금 1중량%를 포함할 수 있다That is, the skin whitening composition for oral administration according to one embodiment of the present invention preferably contains 42 to 72 wt% of glucose (anhydrous crystalline glucose), 2 to 8 wt% of taurine, 2 to 8 wt% of glutathione (L-glutathione yeast extract), 1 to 5 wt% of vitamin C, and 0.5 to 1.5 wt% of refined salt with respect to the total weight (100 wt%) of the composition. More preferably, the skin whitening composition for oral administration according to one embodiment of the present invention may contain 47 to 57 wt% of glucose (anhydrous crystalline glucose), 3 to 7 wt% of taurine, 3 to 7 wt% of glutathione (L-glutathione yeast extract), 2 to 4 wt% of vitamin C, and 0.75 to 1.25 wt% of refined salt with respect to the total weight of the composition. And, most preferably, the oral skin whitening composition according to one embodiment of the present invention may contain 56.83 wt% of glucose (anhydrous crystalline glucose), 5 wt% of taurine, 5 wt% of glutathione (L-glutathione yeast extract), 3 wt% of vitamin C, and 1 wt% of refined salt based on the total weight thereof.
포도당은 인체 내에서의 필수 원소이며, 세포 호흡을 통해 분해되어 에너지를 만들고, 특히 뇌와 적혈구에 중요한 에너지 공급원으로 작용한다. 포도당은 단당류의 한 종류로 이당류(포도당+포도당), 설탕(포도당+과당), 젖당(포도당+갈락토스)등의 재료이자, 글리코젠, 녹말, 셀룰로스 등 다당류의 구성성분이다. 우리 인체는 혈당의 농도를 일정한 범위로 유지시키기 위해 인슐린과 글루카곤이라는 호르몬을 통해 혈당량을 조절하며,혈액 내 포도당의 농도가 높을 경우 인슐린이 분비되어 포도당을 간과 근육으로 이동시키고 남은 포도당은 글리코젠으로 합성하여 간과 근육에 저장되도록 하는 반면,혈액 내 포도당의 농도가 낮을 경우에는 글루카곤이 분비되어 간 속의 글리코젠을 분해하여 포도당을 생성시킴으로써 혈당을 정상 수치로 유지시키고 있다.Glucose is an essential element in the human body. It is broken down through cellular respiration to create energy, and is an important energy source, especially for the brain and red blood cells. Glucose is a type of monosaccharide and is a material for disaccharides (glucose + glucose), sucrose (glucose + fructose), lactose (glucose + galactose), and a component of polysaccharides such as glycogen, starch, and cellulose. Our body regulates blood sugar levels within a certain range through hormones called insulin and glucagon. When the concentration of glucose in the blood is high, insulin is secreted to move glucose to the liver and muscles, and the remaining glucose is synthesized into glycogen and stored in the liver and muscles, whereas when the concentration of glucose in the blood is low, glucagon is secreted to break down glycogen in the liver to create glucose, thereby maintaining blood sugar levels at a normal level.
타우린은 아미노산의 일종으로 인체의 다양한 생리활성에 필요한 성분으로, 쓸개즙을 만드는 것 외에도 많은 생물학적 기능을 하며 근골격계를 만들고 심혈관계가 기능을 유지하는데 필수적임. 뇌혈관장벽을 통과할 수 있어서 신경전달물질을 막고,해마의 기능을 강화시키는 등 중추신경계의 기능을 조절할 수도 있다. 또한, 타우린은 체내 활성산소를 막고,삼투압을 조절하며 칼슘의 항상성을 지킬 수 있고,지방조직을 조절해 비만을 억제하는 역할을 하는 것으로도 알려져 있다.Taurine is a type of amino acid that is necessary for various physiological activities of the human body. In addition to making bile, it has many biological functions and is essential for making the musculoskeletal system and maintaining the function of the cardiovascular system. It can pass through the blood-brain barrier, so it can regulate the functions of the central nervous system, such as blocking neurotransmitters and strengthening the function of the hippocampus. In addition, taurine is known to block active oxygen in the body, regulate osmotic pressure, maintain calcium homeostasis, and control adipose tissue to suppress obesity.
글루타치온은 글루탐산,시스테인, 글리신의 세 가지 아미노산으로 이루어진 결정성 펩타이드로, 미생물과 동식물의 세포 내에 존재하는 항산화제이다. 글루타치온은 환원형와 산화형의 형태로 인체 내 합성되지만 인체가 노화함에 따라 글루타치온 함량과 대사 효소가 감소하게 된다. 인체 내에 발생하는 대사산물과 자유라티칼(free radical), 외부적 환경 요인에 의해 발생하는 독소로 인해 인체의 기능 저하와 면역력 저하,그리고 만성 피로로 노화가 가속화되어 각종 질병에 노출되기 쉬운데, 글루타치온은 원인 물질에 직접적인 해독작용을 돕는 것으로 알려져 있다. 또한, 글루타치온은 산화적 스트레스(oxidative damage)에 대한 항산화제로 활성 산소로 인한 세포의 중요 성분 손상을 방지할 수 있으며,간질환 개선, 당뇨병 치료,항암 활성 등다양한 약리 효과에 관해 보고되고 있다. 이러한 글루타치온은 본 발명에 있어서 비타민 C와 함께 피부 미백효과를 발휘한다.Glutathione is a crystalline peptide composed of three amino acids, glutamic acid, cysteine, and glycine, and is an antioxidant that exists in the cells of microorganisms, plants, and animals. Glutathione is synthesized in the human body in reduced and oxidized forms, but as the human body ages, glutathione content and metabolic enzymes decrease. Due to metabolic products and free radicals generated in the human body, toxins generated by external environmental factors, the human body's functions decline, immunity decreases, and aging is accelerated due to chronic fatigue, making it susceptible to various diseases. Glutathione is known to help directly detoxify the causative agent. In addition, glutathione is an antioxidant for oxidative damage, and can prevent damage to important components of cells due to active oxygen. It has been reported to have various pharmacological effects, such as improving liver disease, treating diabetes, and anticancer activity. In the present invention, glutathione exhibits a skin whitening effect together with vitamin C.
비타민 C는 아스코르브산이라고도 하며, 콜라겐을 합성하고 항산화제로의 작용을 한다. 또한, 비타민 C는 소장에서 철분의 흡수를 돕고 카르니틴의 생합성 및 면역기능에 관여하는 것으로 알려져 있다. 비타민 C가 부족하면 괴혈병,콜라겐 합성의 이상으로 결체조직의 이상,뼈통증, 골절, 설사 등이 일어나며,과잉 시에는 메스꺼움, 복통, 설사 등의 위장관 장애가 일어날 수 있다. 이러한 비타민 C는 본 발명에 있어서 글루타치온과 함께 피부 미백효과를 발휘하며, 글루타치온 생성을 촉진한다.Vitamin C, also known as ascorbic acid, synthesizes collagen and acts as an antioxidant. In addition, vitamin C is known to help the absorption of iron in the small intestine and to be involved in the biosynthesis of carnitine and immune function. If vitamin C is insufficient, scurvy, abnormalities in collagen synthesis, abnormalities in connective tissue, bone pain, fractures, diarrhea, etc. may occur, and if it is excessive, gastrointestinal disorders such as nausea, abdominal pain, and diarrhea may occur. This vitamin C, together with glutathione in the present invention, exerts a skin whitening effect and promotes glutathione production.
한편, 본 발명의 일 실시예에 따른 경구 투여용 피부 미백 조성물은 다른 기능성 구성성분으로, 오렌지과즙 분말, 구연산나트륨, 오렌지향 분말, DL-사과산, 오렌지칼라 SMP, 효소처리 스테비아, 수크랄로스, 비오틴 혼합제제, 비타민 B6 염산염, 비타민 B1 염산염 및 비타민 B12 혼합제제를 더 포함한다.Meanwhile, the oral skin whitening composition according to one embodiment of the present invention further includes other functional components, such as orange juice powder, sodium citrate, orange flavor powder, DL-malic acid, orange color SMP, enzyme-treated stevia, sucralose, biotin mixture, vitamin B6 hydrochloride, vitamin B1 hydrochloride, and vitamin B12 mixture.
여기서, 본 발명의 일 실시예에 따른 경구 투여용 피부 미백 조성물은 그 전체 중량(100중량%)에 대하여 오렌지과즙 분말 5~15중량%, 구연산나트륨 5~15중량%, 오렌지향 분말 2.5~7.5중량%, DL-사과산 2~4중량%, 효소처리 스테비아 0.5~1.5중량%, 오렌지칼라 SMP 0.05~0.15중량%, 수크랄로스 0.01~0.05중량%, 비오틴 혼합제제 0.005~0.015중량%, 비타민 B6 염산염 0.005~0.015중량%, 비타민 B1 염산염 0.005~0.015중량%, 히알루론산 혼합제제 0.001~0.009중량% 및 비타민 B12 혼합제제 0.001~0.009중량%를 더 포함하는 것이 바람직하다.Here, it is preferable that the oral skin whitening composition according to one embodiment of the present invention further contains 5 to 15 wt% of orange juice powder, 5 to 15 wt% of sodium citrate, 2.5 to 7.5 wt% of orange flavor powder, 2 to 4 wt% of DL-malic acid, 0.5 to 1.5 wt% of enzyme-treated stevia, 0.05 to 0.15 wt% of orange-colored SMP, 0.01 to 0.05 wt% of sucralose, 0.005 to 0.015 wt% of biotin mixture, 0.005 to 0.015 wt% of vitamin B6 hydrochloride, 0.005 to 0.015 wt% of vitamin B1 hydrochloride, 0.001 to 0.009 wt% of hyaluronic acid mixture, and 0.001 to 0.009 wt% of vitamin B12 mixture, based on the total weight (100 wt%) of the composition.
그리고, 가장 바람직하게 본 발명의 일 실시예에 따른 경구 투여용 피부 미백 조성물은 그 전체 중량에 대하여 오렌지과즙 분말 10중량%, 구연산나트륨 10중량%, 오렌지향 분말 5중량%, DL-사과산 3중량%, 효소처리 스테비아 1중량%, 오렌지칼라 SMP 0.1중량%, 수크랄로스 0.03중량%, 비오틴 혼합제제 0.01중량%, 비타민 B6 염산염 0.01중량%, 비타민 B1 염산염 0.01중량%, 히알루론산 혼합제제 0.005중량% 및 비타민 B12 혼합제제 0.005중량%를 더 포함할 수 있다.And, most preferably, the oral skin whitening composition according to one embodiment of the present invention may further include 10 wt% of orange juice powder, 10 wt% of sodium citrate, 5 wt% of orange flavor powder, 3 wt% of DL-malic acid, 1 wt% of enzyme-treated stevia, 0.1 wt% of orange-colored SMP, 0.03 wt% of sucralose, 0.01 wt% of biotin mixture, 0.01 wt% of vitamin B6 hydrochloride, 0.01 wt% of vitamin B1 hydrochloride, 0.005 wt% of hyaluronic acid mixture, and 0.005 wt% of vitamin B12 mixture, based on the total weight of the composition.
이하, 본 발명의 바람직한 실시예와 그에 대한 시험 결과를 설명함으로써, 본 발명의 구성성분 및 작용효과를 더 상세히 설명하기로 한다. 다만, 이는 본 발명의 바람직한 예시로 제시된 것이며, 이하에서 개시되는 실시예들에 의해 본 발명이 제한되거나 한정되는 것은 아니다.Hereinafter, the components and effects of the present invention will be described in more detail by describing preferred embodiments of the present invention and test results thereof. However, these are presented as preferred examples of the present invention, and the present invention is not limited or restricted by the embodiments disclosed below.
1. 본 발명의 바람직한 실시예의 구성성분 및 함량1. Composition and content of preferred embodiment of the present invention
본 시험에 적용되는 본 발명의 바람직한 실시예에 따른 경구 투여용 피부 미백 조성물은 그 전체 중량(100중량%)에 대하여 포도당(무수결정 포도당) 56.83중량%, 타우린 5중량%, 글루타치온(L-글루타치온 효모추출물) 5중량%, 비타민 C 3중량% 및 정제소금 1중량%를 구성성분으로 포함하여 시험 대상자가 적정량의 물과 혼합하여 섭취하도록 분말 혹은 가루 제형으로 제조되었다.A skin whitening composition for oral administration according to a preferred embodiment of the present invention applied to this test comprises 56.83 wt% of glucose (anhydrous crystalline glucose), 5 wt% of taurine, 5 wt% of glutathione (L-glutathione yeast extract), 3 wt% of vitamin C, and 1 wt% of refined salt as components based on the total weight (100 wt%) of the composition, and is manufactured in a powder or powder form for the test subject to ingest by mixing it with an appropriate amount of water.
여기서, 본 시험에 적용되는 본 발명의 바람직한 실시예에 따른 경구 투여용 피부 미백 조성물은 시험 대상자가 섭취하기 편하게 한 포당 10g 단위로 포장되었는데, 한 포당(10g) 무수결정포도당 5,683 mg, 타우린 500 mg, L-글루타치온 효모추출물 500 mg, 비타민 C 300 mg, 정제소금 100 mg을 함유한다.Here, the oral skin whitening composition according to a preferred embodiment of the present invention applied to this test is packaged in units of 10 g per pack for easy ingestion by test subjects, and contains 5,683 mg of anhydrous crystalline glucose, 500 mg of taurine, 500 mg of L-glutathione yeast extract, 300 mg of vitamin C, and 100 mg of refined salt per pack (10 g).
또한, 본 시험에 적용되는 본 발명의 바람직한 실시예에 따른 경구 투여용 피부 미백 조성물은 그 외 구성성분으로 그 전체 중량에 대하여 오렌지과즙 분말 10중량%, 구연산나트륨 10중량%, 오렌지향 분말 5중량%, DL-사과산 3중량%, 효소처리 스테비아 1중량%, 오렌지칼라 SMP 0.1중량%, 수크랄로스 0.03중량%, 비오틴 혼합제제 0.01중량%, 비타민 B6 염산염 0.01중량%, 비타민 B1 염산염 0.01중량%, 히알루론산 혼합제제 0.005중량% 및 비타민 B12 혼합제제 0.005중량%를 더 포함한다.In addition, the oral skin whitening composition according to a preferred embodiment of the present invention applied to this test further comprises, as other components, 10 wt% of orange juice powder, 10 wt% of sodium citrate, 5 wt% of orange flavor powder, 3 wt% of DL-malic acid, 1 wt% of enzyme-treated stevia, 0.1 wt% of orange color SMP, 0.03 wt% of sucralose, 0.01 wt% of biotin mixture, 0.01 wt% of vitamin B6 hydrochloride, 0.01 wt% of vitamin B1 hydrochloride, 0.005 wt% of hyaluronic acid mixture, and 0.005 wt% of vitamin B12 mixture, based on the total weight of the composition.
2. 시험 개요 및 시험 방법2. Test Overview and Test Method
위와 같은 구성성분 및 함량으로 분말 혹은 가루 제형의 한 포 단위로 제조된 본 실시예에 따른 경구 투여용 피부 미백 조성물 제품을 인체 적용 시험을 통해 6주 동안 섭취한 섭취군(시험군) 36명과 본 실시예에 따른 경구 투여용 피부 미백 조성물 제품을 섭취하지 않은 비섭취군(대조군) 38명에 대하여 모공,주름, 색소 등의 안면 피부 변화를 관찰하였으며, 여러 항목의 혈액검사를 통해 안정성을 평가하였다.In a human application test, 36 subjects (test group) who took the oral skin whitening composition product manufactured in a powder or powder formulation unit according to the present example with the above components and contents for 6 weeks and 38 subjects (control group) who did not take the oral skin whitening composition product according to the present example were observed for changes in facial skin such as pores, wrinkles, and pigmentation, and stability was evaluated through blood tests for various items.
여기서, 시험 대상자는 만 20~49세의 건강한 여성으로 선정하되, 감염성 질환 종양 소화기계 장애 등 기저질환을 가진 자, 과민증이 있는 자, 아나필락시스 반응 병력이 있는 자, 가족 중 자가면역질환이 진행 중이거나 과거 병력이 있는 자, 정신질환자 등 시험 담당자의 판단에 의해 부적절하다고 판단되는 자는 제외하였다. 그리고, 시험에 참여하는 모든 대상자는 추적관찰기간 동안 외래를 정해진 기간마다 방문하여 섭취 전과 섭취 후 6주째에 혈액 검사, 피부 상태 측정 등을 실시하였으며, 본 실시예에 따른 경구 투여용 피부 미백 조성물 제품의 섭취에 대한 전반적인 만족도와 섭취 순응도를 설문 조사를 통해 확인하고, 이상반응 및 합병증을 조사하였다. 이때, 섭취군(시험군)과 비섭취군(대조군)에서 동일한 프로토콜을 적용하였으며, 추적관찰기간 역시 동일하게 적용하였다.Here, the test subjects were selected as healthy women aged 20 to 49 years, but those with underlying diseases such as infectious diseases, tumors, digestive system disorders, hypersensitivity, a history of anaphylactic reactions, family members with ongoing or past autoimmune diseases, and mental illnesses, etc., who were judged to be unsuitable by the test manager, were excluded. In addition, all subjects participating in the test visited the outpatient clinic at set intervals during the follow-up observation period and underwent blood tests and skin condition measurements before and after intake for 6 weeks. In addition, the overall satisfaction with the intake of the skin whitening composition for oral administration according to this example and the intake compliance were confirmed through a questionnaire, and adverse reactions and complications were investigated. At this time, the same protocol was applied to the intake group (test group) and the non-intake group (control group), and the follow-up observation period was also applied equally.
섭취군은 본 실시예에 따른 경구 투여용 피부 미백 조성물 제품을 한 포당 물 250~350㎖에 혼합하여 하루 두 포씩 섭취하도록 하였으며, 섭취군과 비섭취군의 기본 조건은 아래의 [표 1]과 같이 각 항목 모두 통계적으로 차이 없게 설정되었다. 이때, 수축기 혈압과 이완기 혈압,맥박 모두 섭취군과 비섭취군에서 6주 전과 후의 차이가 없었으며,피부 분석 면적 역시 통계적으로 차이 없게 설정되었다.The intake group mixed the oral skin whitening composition product according to this example into 250-350㎖ of water and took two packets a day. The basic conditions of the intake group and the non-intake group were set so that there was no statistical difference in all items, as shown in [Table 1] below. At this time, there was no difference in systolic blood pressure, diastolic blood pressure, or pulse between the intake group and the non-intake group before and after 6 weeks, and the skin analysis area was also set so that there was no statistical difference.
3. 시험 결과 및 분석3. Test Results and Analysis
섭취군과 비섭취군의 섭취 전과 섭취 6주 후의 피부 측정 결과를 아래의 [표 2]로 정리하였다. Mark Vu (PSI Plus®) 피부 측정기를 이용하여 모공,주름,색소침착,멜라닌,홍조,브라운색소, 피지,포피린,피부톤, 광채 면적, 광채 밝기,수분 항목을 측정하였는데, 아래의 [표 2]에 나타난 바와 같이 섭취군에서 멜라닌과 브라운색소 항목의 수치가 통계적으로 유의하게 개선된 것으로 확인되었다.The skin measurement results before and after 6 weeks of intake and non-intake of the intake group are summarized in [Table 2] below. Using a Mark Vu (PSI Plus®) skin measuring device, the following items were measured: pores, wrinkles, pigmentation, melanin, redness, brown pigment, sebum, porphyrin, skin tone, radiance area, radiance brightness, and moisture. As shown in [Table 2] below, it was confirmed that the values of melanin and brown pigment items in the intake group were statistically significantly improved.
참고로, Mark Vu (PSI Plus®) 피부 측정기는 LED 광원(일반광, 편광, 광택광, UV광)을 이용하여 피부 상태를 정밀하게 측정 분석하는 장치로, 모공, 주름, 피부톤(밝기), 광채, 색소침착, 멜라닌, 피지, 포피린 등을 측정 분석할 수 있다.For reference, the Mark Vu (PSI Plus®) skin analyzer is a device that precisely measures and analyzes skin conditions using LED light sources (normal light, polarized light, glossy light, UV light), and can measure and analyze pores, wrinkles, skin tone (brightness), radiance, pigmentation, melanin, sebum, porphyrin, etc.
섭취군의 섭취 전과 섭취 6주 후의 혈액 검사 결과를 아래의 [표 3]으로 정리하였다. Hb Ale (당화혈색소)의 수치를 제외하고는 섭취 전과 섭취 6주 후의 혈액 검사 결과에서 통계적으로 유의한 차이가 없어 6주간 섭취의 안정성이 확인되었고, 당화혈색소 수치는 5.3에서 5.1로 참고치 내에서 통계적으로 유의하게 개선된 것으로 확인되었다.The blood test results of the intake group before and after 6 weeks of intake are summarized in [Table 3] below. Except for the level of Hb Ale (glycated hemoglobin), there was no statistically significant difference in the blood test results before and after 6 weeks of intake, confirming the stability of the intake for 6 weeks. In addition, the level of glycated hemoglobin was confirmed to have statistically significantly improved within the reference value from 5.3 to 5.1.
본 발명은 전술한 실시예들에 한정되는 것이 아니고, 본 발명의 사상 및 범위를 벗어나지 않고 다양하게 수정 및 변형할 수 있음은 이 기술의 분야에서 통상의 지식을 가진 자에게 자명하다. 따라서 그러한 수정예 또는 변형예들은 본 발명의 특허청구범위에 속한다 하여야 할 것이다.The present invention is not limited to the above-described embodiments, and it is obvious to those skilled in the art that various modifications and variations can be made without departing from the spirit and scope of the present invention. Accordingly, such modifications or variations should fall within the scope of the claims of the present invention.
Claims (7)
포도당 및 글루타치온을 구성성분으로 포함하고,
상기 글루타치온은 L-글루타치온 효모추출물로 제공되며,
비타민 C를 구성성분으로 더 포함하고,
타우린 및 정제소금을 구성성분으로 더 포함하며,
오렌지과즙 분말, 구연산나트륨, 오렌지향 분말, DL-사과산, 효소처리 스테비아, 오렌지칼라 SMP, 수크랄로스, 비오틴 혼합제제, 비타민 B6 염산염, 비타민 B1 염산염, 히알루론산 혼합제제 및 비타민 B12 혼합제제를 구성성분으로 더 포함하는 경구 투여용 피부 미백 조성물로,
상기 경구 투여용 피부 미백 조성물은 그 전체 중량에 대하여 상기 포도당 56.83중량%, 상기 타우린 5중량%, 상기 글루타치온 5중량%, 상기 비타민 C 3중량%, 상기 정제소금 1중량%, 상기 오렌지과즙 분말 10중량%, 상기 구연산나트륨 10중량%, 상기 오렌지향 분말 5중량%, 상기 DL-사과산 3중량%, 상기 효소처리 스테비아 1중량%, 상기 오렌지칼라 SMP 0.1중량%, 상기 수크랄로스 0.03중량%, 상기 비오틴 혼합제제 0.01중량%, 상기 비타민 B6 염산염 0.01중량%, 상기 비타민 B1 염산염 0.01중량%, 상기 히알루론산 혼합제제 0.005중량% 및 상기 비타민 B12 혼합제제 0.005중량%를 포함하는 것을 특징으로 하는 글루타치온을 포함하는 경구 투여용 피부 미백 조성물.
In a composition for oral administration for hydration and nutrition,
Contains glucose and glutathione as components,
The above glutathione is provided as L-glutathione yeast extract.
Contains additional vitamin C as a component,
It additionally contains taurine and refined salt as ingredients.
A skin whitening composition for oral administration further comprising orange juice powder, sodium citrate, orange flavor powder, DL-malic acid, enzymatically treated stevia, orange color SMP, sucralose, biotin mixture, vitamin B6 hydrochloride, vitamin B1 hydrochloride, hyaluronic acid mixture and vitamin B12 mixture as components,
The above oral skin whitening composition comprises 56.83 wt% of the glucose, 5 wt% of the taurine, 5 wt% of the glutathione, 3 wt% of the vitamin C, 1 wt% of the refined salt, 10 wt% of the orange juice powder, 10 wt% of the sodium citrate, 5 wt% of the orange flavor powder, 3 wt% of the DL-malic acid, 1 wt% of the enzyme-treated stevia, 0.1 wt% of the orange color SMP, 0.03 wt% of the sucralose, 0.01 wt% of the biotin mixture, 0.01 wt% of the vitamin B6 hydrochloride, 0.01 wt% of the vitamin B1 hydrochloride, 0.005 wt% of the hyaluronic acid mixture, and 0.005 wt% of the vitamin B12 mixture, based on the total weight of the composition.
상기 경구 투여용 피부 미백 조성물은
분말 제형으로 제조되어 사용자가 이를 적정량의 물에 혼합하여 섭취하는 것을 특징으로 하는 글루타치온을 포함하는 경구 투여용 피부 미백 조성물.In the first paragraph,
The above oral skin whitening composition
An oral skin whitening composition comprising glutathione, characterized in that it is manufactured in a powder form and is taken by the user by mixing it with an appropriate amount of water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230082776A KR102796519B1 (en) | 2023-06-27 | 2023-06-27 | Skin whitening composition for oral administration comprising glutathione |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230082776A KR102796519B1 (en) | 2023-06-27 | 2023-06-27 | Skin whitening composition for oral administration comprising glutathione |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20250000693A KR20250000693A (en) | 2025-01-03 |
| KR102796519B1 true KR102796519B1 (en) | 2025-04-18 |
Family
ID=94241407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230082776A Active KR102796519B1 (en) | 2023-06-27 | 2023-06-27 | Skin whitening composition for oral administration comprising glutathione |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102796519B1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200110561A (en) * | 2019-03-15 | 2020-09-24 | 양원동 | Antioxidant and immunity enhancing composition comprising glutathione enzyme as an active ingredient |
-
2023
- 2023-06-27 KR KR1020230082776A patent/KR102796519B1/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 꽃송이님의 블로그, 네이버 블로그, [online], 2021.08.26. [2025.01.03. 검색], 인터넷:<URL : https://blog.naver.com/eod0/222484726353>* |
| 지나님의 블로그, 네이버 블로그, [online], 2023.02.01. [2025.01.03. 검색], 인터넷:<URL : https://blog.naver.com/volcamalca/223001773747>* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250000693A (en) | 2025-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6713082B2 (en) | Composition comprising carbohydrate and peptide material and its use as an energy supplement after or during physical exercise or as a metabolic nutrient for oral consumption | |
| JP5798648B2 (en) | Anti-fatigue agent containing amino acid composition | |
| US7932288B2 (en) | Composition for relieving subjective symptoms of fatigue | |
| CA2689982A1 (en) | Compositions and approaches for increasing diet induced thermogenesis, inducing weight loss and maintaining muscle mass and strength | |
| TWI517793B (en) | Contains the composition of imidazole peptides and quercetin glycosides | |
| Yonei et al. | Effects on the human body of a dietary supplement containing L-carnitine and Garcinia cambogia extract: a study using double-blind tests | |
| ES2337495T3 (en) | COMPOSITIONS THAT INCLUDE PROTEIN HYDROLYZED EPIGALOCATECINE GALATE. | |
| US20150087679A1 (en) | Nutritional sleep supplement | |
| WO2014069660A1 (en) | Blood flow promoting agent | |
| US20030104107A1 (en) | Energy drink formula and method | |
| WO1997043912A1 (en) | Food composition for lowering body fat content and improving body composition and method therefor | |
| US20040043442A1 (en) | Use of betaine in functional products having blood pressure lowering effects | |
| JP2008510494A (en) | Compositions and methods for deactivation of catabolic processes and protein synthesis in skeletal muscle | |
| CA2514687A1 (en) | Advenced vitamin c-based composition with enhanced biotransformation and utilization of protein and l-carnitine for nutritional supplementation or the like | |
| CN107624068A (en) | The application method of composition and such composition comprising cinnamic acid and zinc | |
| KR102796519B1 (en) | Skin whitening composition for oral administration comprising glutathione | |
| EP1108429A2 (en) | An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases | |
| JP2001224334A (en) | Beauty food containing amino acid | |
| KR101782132B1 (en) | Health care food of composition comprising the extract material in Ginkgo biloba and Plantago ovata | |
| CN101322559B (en) | Multifunctional high-efficient calcium replenishing agent | |
| CA2757351C (en) | Anti-mental fatigue drug | |
| JP2005263706A (en) | Fat metabolism promoting composition and food and drink containing the same | |
| KR20050115017A (en) | Functional food composition having obesity control effect and the preparation method thereof | |
| CN101370555A (en) | Novel application of (-)-epigallocatechin gallate | |
| RU2609874C1 (en) | Alcohol-free beverage "complete amino liquid" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20230627 |
|
| PA0201 | Request for examination |
Patent event code: PA02011R01I Patent event date: 20230627 Comment text: Patent Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20230627 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20230627 Patent event code: PA03021R01I Comment text: Patent Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240508 Patent event code: PE09021S01D |
|
| PN2301 | Change of applicant |
Patent event date: 20241021 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20250103 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250325 |
|
| PG1601 | Publication of registration |